Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

INTRODUCTION: This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing multiple sclerosis (RMS) after suboptimal response to glatiramer acetate (GA; “first switch” patients), including patients with early MS (“early...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurol Ther
Main Authors: Repovic, Pavle, Robertson, Derrick, Kresa-Reahl, Kiren, Cohan, Stanley L., Su, Ray, Avila, Robin, Koulinska, Irene, Mendoza, Jason P.
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140000/
https://ncbi.nlm.nih.gov/pubmed/33225410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-020-00223-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki